- $45.59m
- $71.25m
- $80.28m
Brief: Tela Bio Inc Says Public Offering Of 4.75 Million Common Shares Priced At $9.50 Per Share
Brief: TELA Bio Announces Proposed Public Offering Of Common Stock
Aroa Biosurgery remains among top picks in medtech post Enivo clearance - Canaccord
Tela Bio rises on marketing clearance for cosmetic surgery implant
Brief: TELA Bio Announces Clearance For Ovitex PRS Long-Term Resorbable For Plastic And Reconstructive Surgery
Tela Bio Inc Reports Results For The Quarter Ended In December: Earnings Summary
Brief: Tela Bio Reports Fourth Quarter Results
Tela Bio Inc Expected To Post A Loss Of 55 Cents A Share: Earnings Preview
Brief: Tela Bio Announces U.S. Commercial Launch Of Two New Ovitex® Lpr Device Configurations To Repair Large Abdominal Hernias Using Robotic And Laparoscopic Techniques
Brief: Tela Bio Awarded Biosynthetic Mesh Products Agreement With A National Group Purchasing Organization
Brief: Tela Bio Announces U.S. Commercial Launch Of Its Restoration Solution To Heal Surgical Wounds
REUTERS NEWS SCHEDULE AT 10 a.m. GMT/ 6 a.m. ET
Tela Bio Inc Reports Results For The Quarter Ended In September: Earnings Summary
Brief: Tela Bio Reports Third Quarter 2022 Financial Results
Tela Bio Inc Expected To Post A Loss Of 63 Cents A Share: Earnings Preview
Brief: Tela Bio Announces Publication Of 24-Month Bravo Study Results Demonstrating Benefits Of Ovitex® Reinforced Tissue Matrix In Hernia Repair
TELA Bio drops on pricing stock deal
Brief: Tela Bio Announces Pricing Of Public Offering OF 4.00 Million Common Shares Priced At $8.00per Share
Brief: TELA Bio Announces Proposed Public Offering Of Common Stock